
CSL
CSLLY | OTC
$34.00
-$0.41 (-1.19%)
At close: Nov 16, 2026, 3:59 PM ET
$34.00
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 3:59 PM ET
CSL Company Profile
Company profile explainedCompany Profile
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.
Key Executives
| Name | Position |
|---|---|
| Gordon Naylor DipCompSc | MD, Chief Executive Officer & Executive Director |
| Amy Van Buren | Chief People Officer |
| Ken Lim | Chief Financial Officer |
| Gregory Boss | Executive VP of Legal & Group General Counsel |
| Herve Gisserot | Executive VP of Business Development & Enterprise Alliance Management |
| Kate Sophie Priestman | Chief Corporate & External Affairs Officer |
| Mark Dehring | Head of Investor Relations |
| Mark Hill | Chief Digital Information Officer & Executive Vice President |
| Mary Oates | Executive VP & COO |
| Michelle Rees | Head of Investor Relations |
| Stephen Marlow | Executive VP & GM of CSL Plasma |
| William Mezzanotte | Chief Medical Officer, Executive Vice President and Head of Research & Development |
CSL

| Country | Australia |
| IPO Date | Dec 29, 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29,000 |
| CEO | Gordon Naylor DipCompSc |
Contact Details
655 Elizabeth Street Melbourne,
VIC 3000 Australia
Stock Details
| Ticker Symbol | CSLLY |
| Exchange | OTC |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001274152 |
| CUSIP Number | 12637N204 |
| ISIN Number | US12637N2045 |
| SIC Code |
Recent News
- 8 days ago / globenewswire.comBROAD ARROW'S ZÜRICH AUCTION CONCLUDES A REMARKABLE 2026 AUCTION CALENDAR
- 21 days ago / seekingalpha.comCSL Limited (CSLLY) Shareholder/Analyst Call Transcript
- 27 days ago / prnewswire.comCSL appoints Deborah Waterhouse as CEO & Managing Director
- 27 days ago / reuters.comAustralia's CSL appoints Deborah Waterhouse as CEO
- 1 month ago / zacks.comHRMY vs. CSLLY: Which Stock Is the Better Value Option?
- 1 month ago / prnewswire.comCSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras
- 1 month ago / proactiveinvestors.comCSL strikes US$1.6 billion licensing deal for rare disease drug
- 1 month ago / reuters.comCSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis
- 1 month ago / prnewswire.comCSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
- 2 months ago / reuters.comAustralia's CSL taps Amazon's cloud unit to boost research pipeline
Add to Watchlist
Select watchlists to add or remove CSLLY